On Tuesday, Moderna MRNA got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 73. This exclusive rating ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Moderna MRNA shares soared 10.9% in the last trading session to close at $35.66. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...

Moderna Inc. (NASDAQ: MRNA) is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 ...

I agree to the Terms of Use , Privacy Notice and Cookie Notice.

In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 ...

On January 12, 2026, Moderna reported that it expected unaudited 2025 revenue of about $1.9 billion—slightly above prior guidance—alongside improved projected 2025 GAAP operating expenses of $5.0–$5.2 ...